Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02942264 : TG02 Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of TG02 Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma
PhasePhase 1/Phase 2
AgesMin: 18 Years Max: 99 Years

- Inclusion criteria are same in both Phase I and Phase II parts, except for the number
of prior disease relapses

- Patients must have pathologic diagnosis of anaplastic astrocytoma defined as WHO grade
III or glioblastoma/gliosarcoma, WHO grade IV, which are confirmed by NCI Laboratory
of Pathology. If the pathology diagnosis is anaplastic glioma or anaplastic
oligoastrocytoma, evidence of either intact 1p/19q chromosomes or molecular features
suggesting astrocytic tumor must be present.

(including, but not limited to ATRX, p53).

- Patients must have recurrent disease, histologically proven or imaging suggestive of
recurrent disease as determined by PI. Prior implantation of Gliadel wafers is
acceptable, if tumor recurrence is confirmed by histologic examination of the
recurrent tumor

- Patients must have the ability to understand and the willingness to sign a written
informed consent document.

- Patients must be greater than or equal to 18 years old.

- No more than two prior disease relapses to be eligible for the phase I portion of the
study and no more than one prior relapse to be eligible for phase II.

- Patients must have undergone prior standard therapy for their primary disease. For
patients with glioblastoma, this would include surgical resection, or biopsy, if safe
resection was not permitted due to the tumor location, radiation and adjuvant
temozolomide. For patients with anaplastic astrocytoma, this would include surgical
resection, radiation and adjuvant chemotherapy PCV or temozolomide.

- Tumor tissue must be available for review to confirm histological diagnosis.

- Tumor block or unstained slides must be available for molecular profiling.

- Karnofsky greater than or equal to 60

- Patients must have adequate bone marrow function (ANC greater than or equal to
1,500/mm^3, platelet count of greater than or equal to 100,000/mm^3, adequate liver
function less than or equal to 3 times upper limit normal and alkaline phosphatase
less than or equal to 2 times upper limit normal, total bilirubin less than or equal
to 1.5mg/dl), and adequate renal function (BUN less than or equal to 1.5 times
institutional normal and serum creatinine less than 1.5 mg/dl prior to registration.
These tests must be performed within 14 days prior to registration.

- Patients must have recovered from the toxic effects of prior therapy to less than
grade 2 toxicity per CTC version 4 except deep vein thrombosis.

- At the time of registration, subject must be removed from prior therapy as follows:

- greater than or equal to (28 days) from any investigational agent,

- greater than or equal to 4 weeks (28 days) from prior cytotoxic therapy,

- greater than or equal to 2 weeks (14 days) from vincristine,

- greater than or equal to 6 weeks (42 days) from nitrosoureas,

- greater than or equal to 3 weeks (21 days) from procarbazine administration,

- greater than or equal to 1 week (7 days) for non-cytotoxic agents, e.g.,
interferon, tamoxifen, thalidomide, cis-retinoic acid, etc. radiosensitizer does
not count.

- Patients having undergone recent resection of recurrent or progressive tumor will be
eligible given all of the following conditions apply:

- At least 2 weeks (14 days) have elapsed from the date of surgery and the patients
have recovered from the effects of surgery.

- Evaluable or measureable disease following resection of recurrent malignant
glioma is not mandated for eligibility into the study.

- To best assess the extent of residual disease post-operatively, a MRI should be
done no later than 96 hours in the immediate post-operative period or at least
within 4 weeks postoperatively, within 14 days prior to registration. If the
96-hour scan is more than 14 days before registration, the scan needs to be
repeated. The patient must have been on a stable steroid dose for at least 5 days
prior to

the baseline MRI. Steroids may be initiated as clinically indicated once baseline imaging
has been completed with a goal of titrating steroids as soon as clinically warranted.

- Patients must have received prior radiation therapy and must have an interval of
greater than or equal to 12 weeks (84 days) from the completion of radiation therapy
to study entry except if there is unequivocal evidence for tumor recurrence (such as
histological confirmation or advanced imaging data such as PET scan) in which case the
principal investigator s discretion may determine appropriate timepoint at which study
therapy may begin.

- Women of childbearing potential must have a negative beta-HCG pregnancy test
documented within 14 days prior to registration. The effects of TG02 on the developing
human fetus are unknown. For this reason, women of childbearing potential must not be
pregnant, must not be breast-feeding, and must practice adequate contraception for the
duration of the study, and for 30 days after the last dose of study medication.

- Male patients on treatment with TG02 must agree to use an adequate method of
contraception for the duration of the study, and for 30 days after the last dose of
study medication as the effects of TG02 on the developing human fetus are unknown.

- Patients must agree to enroll on the NOB Natural History protocol to allow the
assessment of molecular tumor markers.


- Patients who are receiving any other investigational agents. However, prior enrollment
on a study using investigational agents is acceptable as per section

- Patients with prior bevacizumab use for tumor treatment. Patients who received
bevacizumab for symptom management, including but not limited to cerebral edema,
pseudoprogression can be included in the study(To date, there have been no effective
regimens developed for recurrent malignant gliomas that are refractory to bevacizumab.
Inclusion of this patient population may impact the ability to determine the efficacy
of TG02 with TMZ.)

- Any serious medical condition, laboratory abnormality, or psychiatric illness that
would prevent the subject from providing informed consent.

- Any condition, including the presence of clinically significant laboratory
abnormalities, which places the patient at unacceptable risk if he/she were to
participate in the study or confounds the ability to interpret data from the study.
These would include:

- Active infection (including persistent fever) including known history of HIV or
Hepatitis C infection, because these patients are at increased risk of lethal
infections when treated with marrow-suppressive therapy.

- Diseases or conditions that obscure toxicity or dangerously alter drug metabolism

- Serious concurrent medical illness e.g. symptomatic congestive heart failure

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to temozolomide and/or TG02.

- Patients with a history of any other cancer (except non-melanoma skin cancer or
carcinoma in-situ of the cervix or bladder), unless in complete remission and off all
therapy for that disease for a minimum of 3 years are ineligible.

- TG02 is primarily metabolized by CYP1A2 and CYP3A4. Patients receiving any medications
or substances that are strong inhibitors or inducers of CYP1A2 and/or CYP3A4 are

- Patients, who continue to have prolonged QTc (males: greater than 450ms; females:
greater than 470ms as calculated by Fridericia s correction formula) despite normal
electrolyte balance and discontinuation of medications known to prolong QTc, will be
excluded from the study.
LinksPermanent Link to THIS page:      |      Link to official listing
Bethesda, Maryland
Facility: National Institutes of Health Clinical Center
Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office Phone: 888-624-1937
Email not avaialable

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2017 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557

Website Design By
World Wide Websites